SCYX SCYNEXIS, Inc.

NASDAQ
$2.85

SCYNEXIS, Inc. (SCYX) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.43 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.3% since its last earnings release on November 5, 2026.

SCYNEXIS Missed Consensus Estimates
Thursday, November 5, 2026 · 8:20 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · After Close
Earnings Whisper
-
vs ($0.43)
Rev est $2.46M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.19

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About SCYNEXIS, Inc.

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.